DocWire News Editors

DocwireNews

<p><em>2019 has seen some exciting innovations in the Oncology and Hematology pipeline.  Below are a few of the many newly approved products as featured on DocWire News.</em></p>
<h3>1: FDA Expands Use of Breast Cancer Drug to Include Men</h3>
<p><a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-proposes-mammogram-recommendations/">The U.S. Food and Drug Administration</a> (FDA) expanded the approval of palbociclib (IBRANCE) in combination with endocrine therapy for hormone receptor (HR)-positive, human epidermal growth factor receptor 2-negative advanced or metastatic <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/multiple-pregnancies-breast-cancer/">breast cancer</a> in male patients.</p>
<p><a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-expands-breast-cancer/">Read More</a></p>
<h3 class="entry-title">2: FDA Approves Firstline Lung Cancer Combination</h3>
<p>The U.S. Food and Drug Administration (FDA) approved atezolizumab (TECENTRIQ®) in combination with carboplatin and etoposide for firstline treatment of adults with extensive-stage small cell <a href="https://proddocwire.wpengine.com/docwire-pick/lung-cancer-deaths-women/" target="_blank" rel="nofollow noopener noreferrer">lung cancer</a>.</p>
<p>The decision was based on results from the multicenter, double-blinded, randomized, placebo-controlled, phase III IMpower133 study, which enrolled 403 patients who were randomized 1:1 to receive atezolizumab in combination with carboplatin and etoposide (n=201) or placebo in combination with carboplatin and etoposide (control arm; n=202).</p>
<p><a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-firstline-lung-cancer/">Read More</a></p>
<h3 class="entry-title">3: FDA Approves LONSURF for Gastric Cancers</h3>
<p>The U.S. Food and Drug Administration approved the oral agent trifluridine/tipiracil (LONSURF) to treat adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma who previously received at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, human epidermal growth factor receptor 2/neu-targeted therapy.</p>
<p><a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-approves-treatment-gastric-cancers/">Read More</a></p>
<h3 class="entry-title">4: FDA Approves First Treatment CABLIVI for Rare Blood Disease</h3>
<p>The U.S. Food and Drug Administration approved caplacizumab-yhdp (CABLIVI) injection as the first treatment specifically indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange and immunosuppressive therapy.</p>
<p><a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/caplacizumab-yhdp-rare-blood-disease/">Read More</a></p>
<h3 class="entry-title">5: FDA Approves Non-Chemotherapy Combination for CLL and SLL</h3>
<p>The U.S. Food and Drug Administration approved ibrutinib (IMBRUVICA) in combination with obinutuzumab (GAZYVA) for treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. This is the first non-chemotherapy regimen indicated for this patient population.<span data-ccp-props="{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}"> </span></p>
<p><a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-approves-combination-cll-sll/">Read More</a></p>
<h3 class="entry-title">6: FDA Approves Second-Line Liver Cancer Therapy</h3>
<p>The U.S. Food and Drug Administration approved cabozantinib for patients with hepatocellular carcinoma (HCC) who have previously received sorafenib.</p>
<p>The decision was based on results from the randomized, double-blind, placebo-controlled, phase III, pivotal CELESTIAL trial that was designed to enroll 760 patients with advanced HCC who received prior sorafenib and may have received up to two prior systemic therapies for HCC and had adequate liver function. Patients were enrolled from more than 100 sites in 19 countries and were randomized 2:1 to receive cabozantinib 60 mg once daily or placebo</p>
<p><a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/cancer-therapy-hepatocellular-carcinoma/">Read More</a></p>


Laura Litwin

Exercise Significantly Improves Cancer-Related Fatigue in Patients With Advanced Lung Cancer

Lung Cancer

Rob Dillard

The Importance of Maintaining Health Amid the Holidays

Sleep Disorders

Can Artificial Intelligence Detect Asymptomatic Lung Cancer?

Latest News

6 Cancer Drugs FDA Approved in 2019

Oncology

2019 has seen some exciting innovations in the Oncology and Hematology pipeline.  Below are a few of the many newly approved products as featured on DocWire News. ...

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe